| Literature DB >> 34784706 |
Guglielmo Niccolò Piozzi1, Seon Hahn Kim1.
Abstract
Intersphincteric resection (ISR) is the ultimate anus-sparing technique for low rectal cancer and is considered an oncologically safe alternative to abdominoperineal resection. The application of the robotic approach to ISR (RISR) has been described by few specialized surgical teams with several differences regarding approach and technique. This review aims to discuss the technical aspects of RISR by evaluating point by point each surgical controversy. Moreover, a systematic review was performed to report the perioperative, oncological, and functional outcomes of RISR. Postoperative morbidities after RISR are acceptable. RISR allows adequate surgical margins and adequate oncological outcomes. RISR may result in severe bowel and genitourinary dysfunction affecting the quality of life in a portion of patients.Entities:
Keywords: Intersphincteric resection; Low rectal cancer; Robotic surgical procedures; Surgical technique
Year: 2021 PMID: 34784706 PMCID: PMC8717069 DOI: 10.3393/ac.2021.00836.0119
Source DB: PubMed Journal: Ann Coloproctol ISSN: 2287-9714
Fig. 1.PRISMA (Preferred Reporting Items for Systematic reviews and Meta-analyses) study [21] flow diagram.
Patient and surgical characteristics
| Study | Year | Country | Study period | Study type | No. of patients | Age (yr) | Male sex (%) | BMI (kg/m2) | Distance to AV (cm) | nCRT (%) | ISD | ISR[ | EBL (mL) | IntraOP transfusion (%) | OP time (min) | Conversion rate (%) | Protective stoma (%) | PostOP hospital stay (day) | Time to first flatus (day) | Time to normal diet (day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuo et al. [ | 2014 | Taiwan | 2011–2013 | RCC | 36 | 56 (30–89) | 58 | 23.8 | 3.8 (1.5–5.0) | 78 | T–P | 36/0/0/0 | 80 (20–200) | NR | 486 (315–720) | 0 | 19.4 | 14 (9–27) | 3 (1–6) | 6.4 (4–12) |
| Luca et al. [ | 2016 | Italy | 2008–2012 | RCS | 23 | 60.2 (28–73) | 35 | 24 (16.5–39.7) | 3.2 (2–5) | 78 | P | 0/0/23/0 | 41 | 0 | 296 (228–420) | 0 | 100 | 7.4 ± 1.7 | NR | NR |
| Park et al. [ | 2019 | South Korea | 2009–2015 | RCS | 81/147 | 60.8 ± 11.2 | 72 | 23.7 ± 3.1 | 2.8 ± 1.0 | 100 | T–P | 31/95/21/0 | NR | NR | NR | 1.2 (robotic) | NR | NR | NR | NR |
| Kim et al. [ | 2020 | South Korea | 2010–2017 | RCC | 488 | 58 ± 11 | 58 | 23.7 ± 3.1 | 3.3 ± 1.7 | 50 | TT (87%) | 216/191/81/143 | NR | 5.5 | 193[ | 0 | 73.3 | 8[ | 1.6[ | NR |
| Piozzi et al. [ | 2021 | South Korea | 2008–2018 | RCS | 123 | 57 ± 12 | 72 | 24.0 ± 3.3 | 3.1 ± 0.8 | 74 | T–P | NR | 93 ± 178 | 5 | 305 ± 61 | 0 | 100 | 13 ± 14 | NR | NR |
| Weighted mean | NR | NR | NR | NR | 58 | 62 | 24 | 3.2 | 65 | NR | NR | 84 | 5.2 | 233 | 0.1 | NR | 9.2 | 1.7 | NR |
Values are presented as number or percentage only, median (range), or mean±standard deviation.
BMI, body mass index; AV, anal verge; nCRT, neoadjuvant chemoradiotherapy; ISD, intersphincteric dissection; ISR, intersphincteric resection; EBL, estimated blood loss; IntraOP, intraoperative; OP, operation; PostOP, postoperative; RCC, retrospective case-control study; RCS, retrospective cohort study; P, perineal; T−P, transabdominal and perineal; TT, total transabdominal; NR, not reported.
Partial, subtotal, total, external anal sphincter resection.
Weighted mean.
Tumor characteristics and oncological survival
| Study | Year | Country | Stage[ | DRM (cm) | DRM+ (%) | CRM (mm) | CRM+ (%) | LN | Follw-up (mo) | LR rate (%) | DD (%) | CT (%) | OS, 5 yr (%) | DFS, 5 yr (%) | LRFS, 5 yr (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuo et al. [ | 2014 | Taiwan | NR | 2.2 (0.4–4.2) | 0 | 0.7 (0–1.8) | 4 | 14 (2–33) | NR | NR | NR | NR | NR | NR | NR |
| Luca et al. [ | 2016 | Italy | 3/5/9/6/0 | NR | NR | NR | 4.3 | 20 ± 11 | NR | NR | NR | NR | NR | NR | NR |
| Park et al. [ | 2019 | South Korea | 33/36/42/36/0 | NR | 0.6 | NR | 3.4 | NR | 34 (8–94) | 11.6 | 22.4 | NR | NR | 64.9 (3 yr) | NR |
| Kim et al. [ | 2020 | South Korea | 62/167/106/140/13 | 1.4[ | NR | NR | 1.4 | 18.9[ | 41 (6–95) | 2.5 | 12.9 | NR | 86.7 | 80.7 | NR |
| Piozzi et al. [ | 2021 | South Korea | 14/42/22/30/15 | 1.1 ± 0.8 | NR | 0.4 ± 0.3 | 6.5 | 18.9 ± 12.5 | 57 (2–127) | 10.6 | 26 | 49.6 | 79.1 | 64.1 | 88.1 |
| Weighted means | NR | NR | 1.11 | NR | 0.5 | 2.4 | 18.7 | 43 | 5 | 16 | NR | 85.1 | 77.3 | NR |
Values are presented as number or percentage only, median (range), or mean±standard deviation.
DRM, distal resection margin; CRM, circumferential resection margin; LN, harvested lymph nodes; LR, local recurrence; DD, distal metastases rate; CT, chemotherapy rate; OS, overall survival; DFS, disease-free survival; LRFS, local recurrence-free survival; NR, not reported.
0/I/II/III/IV.
Weighted means.
Postoperative morbidity and mortality
| Study | Year | Complication (%), 30 day | CD classification[ | Anastomotic leakage (%) | Ileus (%) | Neorectum necrosis (%) | Anastomotic stricture (%) | Rectovaginal fistula (%) | Permanent stoma (%) | Mortality (%), 30 day |
|---|---|---|---|---|---|---|---|---|---|---|
| Kuo et al. [ | 2014 | 25 | NR | NR | NR | 14 | 8.3 | 2.8 | NR | NR |
| Luca et al. [ | 2016 | 17.4 | NR | NR | 8.7 | NR | 21.7 | 4.3 | 8.7 | 0 |
| Park et al. [ | 2019 | NR | NR | 10.8 | NR | NR | 1.4 | 6.8 | 0.5 (1 for poor anal function) | 0 |
| Kim et al. [ | 2020 | 15.2 | 13/9/0/9/0 | 3.6 | 5.5 | NR | 3.5 | NR | 2.2 | 0 |
| Piozzi et al. [ | 2021 | 40.7 | 28 (I–II)/22 (III–IV) | 7.3 | 24.4 | NR | NR | NR | NR | 0 |
| Weighted means | 20.5 | 14 | 5.1 | 9.3 | NR | 4.2 | 5.4 | 2.2 | 0 |
CD, Clavien-Dindo; NR, not reported.
I/II/IIIa/IIIb/Iva.
Quality appraisal (risk of bias) for case series studies
| Study | Year | Clear criteria for inclusion | Condition measured in a standard, reliable way | Valid methods used for identification of the condition | Consecutive inclusion | Complete inclusion | Clear reporting of the demographics | Clear reporting of clinical information | Outcomes or follow-up results | Clear reporting of the presenting site/clinic demographic information | Statistical analysis appropriate | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luca et al. [ | 2016 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 10 |
| Park et al. [ | 2019 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 10 |
| Piozzi et al. [ | 2021 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 10 |
Quality appraisal (risk of bias) for case-control studies
| Study | Year | Groups comparable | Cases and controls matched appropriately | Same criteria for identification of cases and controls | Exposure measured in a standard, valid and reliable way | Exposure measured in the same way for cases and controls | Confounding factors identified | Strategies to deal with confounding factors stated | Outcomes assessed in a standard, valid and reliable way for cases and controls | Exposure period of interest long enough | Statistical analysis appropriate | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuo et al. [ | 2014 | Yes | Yes | Yes | Uncertain/not applicable | Uncertain/not applicable | Yes | Yes | Yes | Yes | Yes | 8 |
| Kim et al. [ | 2020 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 10 |
Fig. 2.Trocar positioning for the da Vinci Si (A), Xi (B), and Single-Port (SP) as described by Toh and Kim [45] and Cheong et al. [46]. MCL, midclavicular line. Yellow circle, da Vinci 12-mm port; red circle, 12-mm standard port; blue circle, da Vinci 8-mm port; green circle, 5-mm standard port (assistant); white circle, 25-mm access for SP placement.